Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
Top Cited Papers
- 1 December 2008
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (34) , 5610-5617
- https://doi.org/10.1200/jco.2008.16.7510
Abstract
Purpose Cilengitide, an inhibitor of αvβ3 and αvβ5 integrin receptors, demonstrated minimal toxicity and durable activity across a wide range of doses administered to adults with recurrent glioblas...Keywords
This publication has 27 references indexed in Scilit:
- Molecularly targeted therapy for malignant gliomaCancer, 2007
- EFFECT OF THE ANGIOGENESIS INHIBITOR CILENGITIDE (EMD 121974) ON GLIOBLASTOMA GROWTH IN NUDE MICENeurosurgery, 2006
- Integrins: Molecular targets in cancer therapyCurrent Oncology Reports, 2006
- Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted AgentsThe Oncologist, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- αv‐Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascinInternational Journal of Cancer, 2002
- αvβ3 and αvβ5 Integrin Expression in Glioma PeripheryNeurosurgery, 2001
- Human Malignant Glioma Therapy Using Anti-αVβ3 Integrin AgentsJournal of Neuro-Oncology, 2000
- Expression of Integrin ανβ3 in Small Blood Vessels of Glioblastoma TumorsJournal of Neuropathology and Experimental Neurology, 1996
- Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissueJournal of Neuroimmunology, 1995